Phase-rectified signal averaging as a sensitive index of autonomic changes with aging

L. M. Campana,1,4 R. L. Owens,4,5 G. D. Clifford,2,4,5 S. D. Pittman,3 and A. Malhotra4,5

1Boston University, 2Massachusetts Institute of Technology, 3Philips-Home Healthcare Solutions, 4Brigham and Women’s Hospital, and 5Harvard Medical School, Boston, Massachusetts

Submitted 5 January 2010; accepted in final form 23 March 2010

Campana LM, Owens RL, Clifford GD, Pittman SD, Malhotra A. Phase-rectified signal averaging as a sensitive index of autonomic changes with aging. J Appl Physiol 108: 1668–1673, 2010. First published March 25, 2010; doi:10.1152/japplphysiol.00013.2010.—Standard heart rate variability (HRV) techniques have been questioned in the sleep and autonomic fields as imprecise measures of sympathetic and parasympathetic activity. A new technique has emerged, known as phase-rectified signal averaging (PRSA). PRSA is used to quantify the quasi-periodic accelerations and decelerations in short-term heart rate, an effect that is normally masked by artifacts and noise. When applied to a signal of peak-to-peak (RR) time intervals, these quasiperiodicities can be used to estimate overall vagal activity, quantified as deceleration capacity (DC) and acceleration capacity (AC). We applied the PRSA analysis to a healthy cohort (ages 21–60 yr) enrolled in a clinical sleep trial, in which ECG data during wakefulness and sleep were available. We found that DC and AC were significantly attenuated with increasing age: a 0.27 ms/yr decrease in DC and a 0.29 ms/yr increase in AC (P < 0.001). However, even in the older subjects, DC values were higher than previously found in people post-myocardial infarction. We also found a drop in percentage of normal-to-normal intervals where the higher than previously found in people post-myocardial infarction. We de-
receiving approval of the protocol by their local Institutional Review Board or a central Institutional Review Board. All subjects gave written, informed consent before participation in the study. All subjects underwent a thorough history and physical examination by a licensed physician to exclude all relevant comorbidities. Subjects were healthy adults (ages 21–60 yr) without any sleep disorders, cardiovascular problems, or diabetes, as indicated by the medical history. Subjects did not have insomnia, as assessed by self-reporting at least 6.5–8.5 h sleep/night and confirmed with 7–14 days of actigraphy. PSGs included a single-lead ECG acquired at 500 Hz with 16-bit resolution. The PSG data were used to detect and stage sleep using standard criteria by experienced technologists registered in polysomnography (1, 19). Two 5-min ECG data sets were analyzed using the PRSA technique described below: the 5 min before sleep onset and the 5 min after sleep onset. Sleep onset was defined as the time from lights out to the beginning of the first epoch of 10 min of continuous sleep.

**PRSA methods.** The PRSA technique has been described in detail elsewhere (2, 14). The PRSA algorithm and analysis of the results were performed using Matlab. The PRSA software was benchmarked against the freely available download from the Technical University of Munich (25) on artificial data to ensure accuracy. The PRSA algorithm begins with the detection of the RR intervals in an ECG signal, using a standard peak detection program (13). The next step is to identify each of the remaining data points as either a deceleration or acceleration “anchor.” If an RR interval is increased (slower HR) relative to the previous interval, it is identified as a deceleration anchor, while, if the interval is shorter then the previous interval (faster HR), it is identified as an acceleration anchor (Fig. 1). Any RR intervals that exhibited more than a 20% change from the previous RR interval were eliminated as anchors in the analysis, as they are likely to be related to measurement noise or ectopic beats (10).

After the deceleration and acceleration anchors are determined, a window surrounding each anchor is created. The window is defined by the two intervals immediately preceding and following the anchor interval. Note that many of these windows will overlap, as the anchor points are usually close to one another. All of the deceleration (or acceleration) windows are then aligned at the anchor point (phase rectified). Once aligned, the respective intervals are averaged together (Fig. 2). Once averaged, the DC and AC are calculated using Eq. 1.

\[
DC \text{ or } AC = \left[ \frac{RR(0) + RR(1) - RR(-1) - RR(-2)}{4} \right] \quad (1)
\]

where RR(0) is defined as the RR interval at the anchor (interval 0, the current interval), while RR(1) is the next RR interval, and so on.

**HRV methods.** In addition to PRSA, traditional HRV metrics were calculated. The power spectral density of the linearly detrended RR intervals was calculated using the Lomb periodogram (17, 22). LF power was defined as the total power in the spectra from 0.015 to 0.15 Hz. HF power was defined as the total power in the spectra from 0.15 to 0.4 Hz (19). We normalized LF and HF by the total power in the spectra from 0.0 to 0.5 Hz. The percentage of normal-to-normal intervals where the current interval deviated >50 ms from the previous interval (pNN50), another possible marker of parasympathetic tone (7, 12), was calculated. HR was calculated by averaging the intrabeat intervals in the 5-min segment, and the standard deviation of the intrabeat intervals was calculated as well. All variables were analyzed in the 5-min period of wakefulness and the 5-min period of sleep and stratified by age.

**Statistics.** Linear regression was performed to evaluate how AC, DC, and pNN50 change with age. F-test was performed on the \( R^2 \) value to evaluate significance. Furthermore, ages were segregated into four groups (20–29, 30–39, 40–49, and 50–60 yr), and the Kruskal-Wallis one-way ANOVA was performed on DC and AC during wakefulness. A Wilcoxon (nonparametric) rank-sum test was used to determine whether PRSA and HRV metrics (LF, HF, and LF-to-HF ratio) were significantly different between each older (>31 yr, based on median) and younger (<31 yr) subjects and between sleep and wakefulness. Values are means ± SD.

**RESULTS**

**Subject demographics.** A total of 166 subjects were analyzed with a mean age of 33.9 ± 10.9 yr (median age 31 yr) and were 64.3% female.

**PRSA.** During wakefulness, anchor points were identified, and, on average, 140 ± 32 windows were used to determine DC and 139 ± 27 windows were used to determine AC in the 5-min period directly preceding sleep for each subject. During NREM sleep, 144 ± 28 anchors were used to determine DC and 145 ± 22 for AC. There was no statistically significant difference in either DC or AC between the 5-min period of wakefulness and the 5-min period of sleep. During wakefulness, there was a significant decrease in DC with increasing age (\( R^2 = 0.12, P < 0.001 \)) (Fig. 3A). For every additional decade, DC decreases by ~3 ms. Furthermore, DC was sig-
significantly higher in the 20- to 29-yr-old group (N = 79) compared with the 40- to 49-yr-old (N = 28) and 50- to 60-yr-old group (N = 20) (Fig. 3B). A similar slope and regression fit was found when comparing AC with age during wakefulness (R² = 0.12, P < 0.001) (Fig. 4A), and AC was significantly different in the 20- to 29- and 30- to 39-yr-old (N = 39) groups compared with the 50- to 60-yr-old group (Fig. 4B).

HRV measurements. pNN50 was also decreased with age (P < 0.001) during the 5-min period of wake before sleep onset (Fig. 5A). Furthermore, subjects in their 20’s had significantly higher pNN50 then those in their 40’s and 50’s, and subjects in their 30’s had significantly higher pNN50 then those in their 50’s (Fig. 5B). No statistically significant differences were seen between the two groups of older (>31 yr) and younger (≤31 yr) patients in LF power, HF power, LF-to-HF ratio, or HR during wakefulness; however, there was a larger standard deviation of HR found in the younger group (Table 1).

DISCUSSION

We show that PRSA measurements, even in a healthy cohort, vary by age. DC and AC show clear decrements with increasing age in otherwise healthy individuals. We hypothesize that the decrement in DC with age is a result of decreased vagal tone in older people, which may be a marker for future cardiovascular disease. While AC is most likely modulated by vagal tone as well, due to the short time scale on which changes occur, we cannot rule out other inputs, and, therefore, the corresponding decline in AC with age is difficult to interpret.

Our results are similar to those from Kandelhart et al. (14), who also found an effect of age on PRSA metrics among people with disease. The authors found a linear relationship between DC and age in a cohort of middle-aged (ages 33–77 yr) post-MI subjects (DC = 12.2 – 0.10 age/yr). Our work adds to the generalizability of the prior research by including people who were ostensibly normal over a wider age range than the existing literature. Interestingly, our healthy subjects had a higher DC than those subjects in the same age range who had a history of coronary artery disease, furthermore the slope of the decrement in DC with age was steeper in our population compared with the Kandelhart study (−0.27 vs. −0.10 ms/age).
in years, respectively). One potential issue is that, in the Kandelhart study, 24-h ECG recordings were used, while, in this study, short 5-min recordings were used. Previous studies have shown that mental and physical activity alters HRV measurements (5, 11, 24) and creates motion artifacts. By using a small section of data with little physical or mental activation (i.e., relaxed wakefulness), the measurement does not have to account for various levels of activity that subjects may have throughout the day in a 24-h recording (which may well be influenced by aging as well). This comparison supports the idea that PRSA metrics can be used to estimate cardiovascular health.

Other correlates of decreased vagal tone are HF power and pNN50. Previous studies have shown decreases in HF power with increasing age (28, 30); however, we found no such decrement in our sample. We believe that, since our population was screened for clinical cardiovascular disease and did not contain any subjects over the age of 60 yr, HF power was not sensitive enough to measure the resultant vagal decrement in this subject pool. We did see a trend of increasing LF-to-HF ratio with increasing age; however, it was not statistically significant. pNN50 has also been shown to be depressed in the elderly (21), and a reduced level of pNN50 correlates with an increased risk of incident hypertension (27). Our results follow those of Mietus et al. (21), yet our study was not designed to assess incident cardiac events in our cohort. We hypothesize that the subjects with very low values of pNN50 and DC will be at the highest risk of disease.

One surprising result is that no changes were seen from wake to sleep in either AC, DC, or pNN50. If AC, DC, and pNN50 characterize the level of vagal activity, one might expect to see increases in both DC and pNN50 and decreases in AC upon sleep onset. One possible explanation is that the period of wakefulness we examined is a highly relaxed state just before sleep onset, and, therefore, large changes are not seen when persistent sleep does occur. However, we anticipate that our results would be different, if we examined active wakefulness rather than relaxed wakefulness before sleep onset. Similarly, once asleep, subjects were recorded during stage I or II non-rapid eye movement (REM) sleep; greater differences might be seen during slow-wave or REM sleep. Alternatively, these particular HRV measurements might reflect the intrinsic properties of the vagal nerve (which likely do not change from wakefulness to sleep) rather than its level of activity, which is modulated by changing levels in activity and wakefulness.

Limitations. Our paper had a number of strengths, including its novelty, our relatively large sample size, our exclusion of comorbidities, and our use of relaxed wakefulness before sleep onset to characterize intrinsic biological properties (rather than behaviors) of our participants. However, we acknowledge the following weaknesses. First, we studied a limited age range, and, therefore, we are unable to draw conclusions about elderly participants (e.g., we studied only 20 individuals above the age of 50 yr). Similarly, we excluded comorbidities based on rigorous history and physical examination, but may have missed subclinical or occult disease based on our study design. Therefore, we accept that our conclusions are not generalizable.

Table 1. Average phase-rectified signal averaging and heart rate variability during wakefulness for younger and older subjects

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>DC, ms</th>
<th>AC, ms</th>
<th>LF</th>
<th>HF</th>
<th>LF/HF</th>
<th>HR, beats/min</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Older (age &gt;31 yr)</td>
<td>81</td>
<td>14.02 ± 6.36</td>
<td>−15.68 ± 7.11</td>
<td>0.18 ± 0.07</td>
<td>0.23 ± 0.10</td>
<td>1.05 ± 1.19</td>
<td>65.34 ± 9.24</td>
<td>0.13 ± 0.07</td>
</tr>
<tr>
<td>Younger (age ≤ 31 yr)</td>
<td>85</td>
<td>19.43 ± 9.68</td>
<td>−21.52 ± 10.13</td>
<td>0.17 ± 0.08</td>
<td>0.25 ± 0.09</td>
<td>0.81 ± 0.53</td>
<td>64.56 ± 9.40</td>
<td>0.16 ± 0.81</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>0.0001*</td>
<td>0.0001*</td>
<td>0.71</td>
<td>0.32</td>
<td>0.20</td>
<td>0.63</td>
<td>0.03*</td>
</tr>
</tbody>
</table>

Values are means ± SD; n, no. of subjects. Phase-rectified signal averaging and traditional heart rate variability metrics in older and younger groups are shown. DC, deceleration capacity; AC, acceleration capacity; LF, low-frequency power; HF, high-frequency power; LF/HF, LF-to-HF ratio; HR, heart rate; SD, standard deviation of HR. *Statistically significant difference between the two age groups.
beyond the study participants. Second, based on our study design, we only examined a 5-min window of ECG activity. We made this decision to assess a stable period of relaxed wakefulness before sleep onset to minimize the influences of activity and behavioral state. We also accept that subsequent research examining longer periods of recording will be of interest. Third, as our ultimate aim is to understand the mechanisms underlying cardiovascular morbidity and mortality, one could argue that we are simply measuring autonomic surrogates rather than true events, such as MI, fatal arrhythmias, or cerebrovascular events. However, we would argue that such large-scale epidemiological studies would be premature before more straightforward, well-controlled physiological assessments have been performed. We would ultimately support further research into the utility of PRSA in predicting hard outcomes. Despite our acknowledged limitations, we believe that our findings are robust and represent an important addition to the existing literature.

Conclusions. We performed PRSA analysis in a young, healthy cohort and found 1) DC values higher than those previously reported, and 2) a decrease in PRSA metrics with aging in a healthy and relatively young population. We did not see an effect of aging in other HRV metrics, suggesting that PRSA is a more sensitive marker of age-related changes in autonomic activity. Future studies must be performed to determine whether this decrement of vagal tone with age is just a natural aging phenomenon, or if it can be used to predict future cardiac events.

ACKNOWLEDGMENTS

Present address of G. D. Clifford: Department of Engineering Science at the University of Oxford, Oxford, UK.

GRANTS

This work was funded by National Institutes of Health (NIH) Grants K24 HL 093218, R01 HL090897, R01 HL085188, and R01 HL73146; American Heart Association Grant 0840159N; and NIH training grant in sleep medicine.

DISCLOSURES

A. Malhotra has consulting and/or research income from Philips, Ethicon, Medtronic, SHC, SGS, Pfizer, Novartis, Sepracor, Cephalon, Apexx, and Itamar. S. D. Pittman is employed by Philips.

REFERENCES

